Literature DB >> 16495627

Staphylococcus aureus nasal carriage and associated factors in type 2 diabetic patients.

Ali Tamer1, Oguz Karabay, Hasan Ekerbicer.   

Abstract

We aimed to compare the rate of nasal carriage of Staphylococcus aureus (NCSA) between type 2 diabetic patients and non-diabetic ones and also to reveal the associated risk factors. Type 2 diabetic subjects were selected from outpatient diabetes clinics and control subjects were selected from outpatient internal medicine clinics in the same hospital. The subjects were divided into 3 groups. Group I included 68 subjects on insulin therapy and dietetic treatment, Group II included 80 subjects on oral anti-diabetic agents and dietetic treatment and Group III included 150 age- and sex-matched non-diabetic subjects. The rates of NCSA for Group I, II and III subjects were found to be 24 (35.3%), 11 (13.8%), and 16 (10.7%), respectively. Whereas there was no significant difference in NCSA positivity between Group II and Group III, a significant difference was found between Groups I and III (P < 0.01). Univariate analysis revealed that the following were significant risk factors for NCSA in our diabetic patients: insulin use, hospital admission within the last 6 months, being diabetic for more than 6 years, fasting glucose level above 111 mg/dl and antibiotic usage within the last 6 months. Furthermore, insulin use (odds ratio 3.32) and antibiotic usage within the last 6 months (odds ratio 5.75) were defined as significant risk factors for NCSA in diabetic subjects by the logistic regression method. Our results suggested that the rate of NCSA was significantly higher in type 2 diabetic patients who used insulin or antibiotics within the last 6 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16495627

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  7 in total

1.  Immunological role of nasal staphylococcus aureus carriage in patients with persistent allergic rhinitis.

Authors:  Maged Mohamed Refaat; Tarek Mansour Ahmed; Zeinab Ahmed Ashour; Mohamed Yousif Atia
Journal:  Pan Afr Med J       Date:  2008-10-30

2.  Novel human microbe-disease association prediction using network consistency projection.

Authors:  Wenzheng Bao; Zhichao Jiang; De-Shuang Huang
Journal:  BMC Bioinformatics       Date:  2017-12-28       Impact factor: 3.169

3.  Prevalence and characteristics of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus nasal colonization among a community-based diabetes population in Foshan, China.

Authors:  Jialing Lin; Ping Xu; Yang Peng; Dongxin Lin; Qianting Ou; Ting Zhang; Chan Bai; Xiaohua Ye; Junli Zhou; Zhenjiang Yao
Journal:  J Diabetes Investig       Date:  2016-12-15       Impact factor: 4.232

4.  Novel human microbe-disease associations inference based on network consistency projection.

Authors:  Shuai Zou; Jingpu Zhang; Zuping Zhang
Journal:  Sci Rep       Date:  2018-05-23       Impact factor: 4.379

5.  Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose.

Authors:  James P Garnett; Emma H Baker; Sonam Naik; Jodi A Lindsay; Gwenan M Knight; Simren Gill; John S Tregoning; Deborah L Baines
Journal:  Thorax       Date:  2013-05-24       Impact factor: 9.139

6.  Fructose transport-deficient Staphylococcus aureus reveals important role of epithelial glucose transporters in limiting sugar-driven bacterial growth in airway surface liquid.

Authors:  James P Garnett; Daniela Braun; Alex J McCarthy; Matthew R Farrant; Emma H Baker; Jodi A Lindsay; Deborah L Baines
Journal:  Cell Mol Life Sci       Date:  2014-05-09       Impact factor: 9.261

7.  Vitamin D and Cathelicidin (LL-37) Status in Patients with Type 2 Diabetes and Staphylococcus aureus Nasal Carriage.

Authors:  Marina N Plataki; Rodanthi Vamvoukaki; George Samonis; Charalampos Bikis; Maria Gorgomiti; John A Papadakis; Sofia Maraki; Diamantis P Kofteridis
Journal:  Rev Diabet Stud       Date:  2021-05-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.